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ABSTRACT
Background: During the course of development of montelukast, a cysteinyl leukotriene receptor 1 antagonist,
for treatment of seasonal allergic rhinitis, a double-blind, non-inferiority study was carried out to evaluate the ef-
ficacy and safety of montelukast 5 mg and 10 mg compared with pranlukast 450 mg, which has a similar
mechanism of action.
Methods: Montelukast 5 mg, 10 mg or pranlukast 450 mg and the corresponding placebo were orally adminis-
tered to patients with seasonal allergic rhinitis three times a day for 2 weeks. Non-inferior efficacy of montelu-
kast 5 mg and 10 mg to pranlukast 450 mg was investigated by the change from the baseline in the composite
nasal symptoms scores over the 2-week treatment period.
Results: Montelukast 5 mg, 10 mg once daily and the pranlukast 450 mgday showed significant improve-
ments in the change from the baseline in the composite, daytime and nighttime nasal symptom scores, and the
improvement lasted for 2 weeks. Montelukast 5 mg and 10 mg were non-inferior to pranlukast 450 mg in the
change from the baseline in the composite nasal symptoms scores. The incidence rates of adverse experi-
ences and drug-related adverse experiences were not significantly different among the three treatment groups.
Conclusions: The results indicate that administration of montelukast 5 mg and 10 mg once daily are potent
alternatives for the treatment of seasonal allergic rhinitis and demonstrated that the efficacy and the safety pro-
files are comparable with pranlukast 450 mgday.
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INTRODUCTION
Montelukast sodium (montelukast) is a cysteinyl leu-
kotriene receptor 1 (CysLT1) specific antagonist that
has been developed primarily for the treatment of
bronchial asthma.1 Montelukast is used for adult and
pediatric patients with bronchial asthma in a number
of countries including Japan. Cysteinyl leukotrienes
(CysLT) and the related substances are physiologi-
cally active chemical mediators that also play an im-
portant role in the pathogenesis of allergic rhinitis.
Since montelukast has been expected to be effective
not only for the treatment of bronchial asthma but
also for improving symptoms associated with allergic
rhinitis based on its mechanisms of actions, its clini-
cal development was initiated. It has been reported
that pranlukast hydrate (pranlukast), a selective an-
tagonist against CysLT1 receptors like montelukast,
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Table 1 Patient demographics and other baseline characteristics
PranlukastMontelukast 10 mgMontelukast 5 mgTreatment group
456454461Eficacy assessment
Gender
211 (46.3)209 (46.0) 219 (47.5) Male
245 (53.7)245 (54.0) 242 (52.5) Female
Age (years)
34.3 ± 9.534.9 ± 10.433.8 ± 10.3Mean ± SD
Body weight (kg)
59.6 ± 9.959.9 ± 11.260.5 ± 11.5Mean ± SD
Disease type
305 (66.9)299 (65.9) 289 (62.7) Seasonal
151 (33.1)155 (34.1) 172 (37.3) Seasonal＋Perennial
Duration of alergic rhinitis (years)
13.5 ± 7.713.7 ± 7.113.2 ± 7.5Mean ± SD
Specific IgE-antibodies
225 (49.3)212 (46.7) 211 (45.8) Only cedar＞― 2
231 (50.7)242 (53.3) 250 (54.2) ＞― 2 types:＞― 2 antibodies
Baseline symptoms scores (Mean ± SD)
2.02 (0.58)2.03 (0.56) 2.00 (0.55) Composite nasal symptom scores
2.44 (0.61)2.43 (0.60) 2.41 (0.59) Daytime nasal symptom scores
1.60 (0.69)1.63 (0.65) 1.59 (0.66) Nightime nasal symptom scores
Number of patients (%).
was efficacious for alleviating nasal congestion, nasal
discharge and sneezing in rhinitis patients.2 It has
been stated in the Practical Guideline for the Man-
agement of Allergic Rhinitis in Japan3,4 that leukot-
riene receptor antagonists are effective primarily for
the treatment of moderate to severe nasal congestion-
type allergic rhinitis. In particular, they are more effi-
cacious against nasal congestion than the second-
generation antihistamines and are as effective as the
second-generation antihistamines against sneezing
and nasal discharge.3,4 At present, pranlukast is the
only leukotriene receptor antagonist that has been ap-
proved for allergic rhinitis, and it has been also
known that pranlukast exerts antagonistic actions
against leukotriene (LT) C4, D4 and E4 receptors.2
Clinical studies of montelukast have been con-
ducted overseas in patients with seasonal and peren-
nial allergic rhinitis and its usefulness was demon-
strated.5 As a result, its indications and usage for al-
lergic rhinitis have been granted in a number of coun-
tries. Also, the incidence of complications of allergic
rhinitis in patients with bronchial asthma is fairly
high6 and morbidity has been rising in Japan. The
clinical development of montelukast has been initi-
ated in an attempt to determine indications and usage
for allergic rhinitis, and in the previous study con-
ducted in patients with seasonal allergic rhinitis7 us-
ing placebo as a control drug, it has been already
demonstrated that montelukast was effective and safe
for oral administration of montelukast 5 mg or 10 mg
once daily at bedtime for two weeks. Thus, we con-
ducted a double blind non-inferiority study of mon-
telukast using pranlukast, as a control drug with a
similar leukotriene receptor antagonist to evaluate
the efficacy and the safety of montelukast in patients
with seasonal allergic rhinitis.
METHODS
PATIENTS
The demographics and other baseline characteristics
of 1375 patients (1371 patients for efficacy analysis),
treated with montelukast 5-mg, 10-mg tablets (Banyu
Pharmaceutical Co., Ltd.), or pranlukast 112.5-mg
capsules (Ono Pharmaceutical Co., Ltd.) are de-
scribed in Table 1. Patients were treated as out pa-
tients at 19 institutions. The seasonal allergic rhinitis
patients who fulfilled the inclusion criteria are listed
as follows: (1) quantitative analysis of specific IgE an-
tibody (UniCAP-RAST) revealed scores 2 points
(IgE antibody containing antibodies against pollen
scattered between February and April, 2004); (2) a
past history of typical seasonal allergic rhinitis at least
for the past two years; (3) age: between 15 and 65
years (male or female); (4) the following three crite-
ria fulfilled for symptoms.3,4 [(1) daytime nasal con-
gestion scores 2 points per day, as an average (to-
tal6 points), (2) total scores of daytime nasal symp-
toms (sneezing attack, nasal discharge and nasal con-
gestion during the daytime)4 points per day, as an
average (total 12 points) and (3) total scores of
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Table 2 Severity of daytime nasal symptoms (DNSS)
Severity
Types
－＋＋＋＋＋＋＋＋＋＋
None1―5 times6―10 times11―20 times＝21 timesSneezing
None1―5 times6―10 times11―20 times＝21 timesNasal discharge(Frequencies) 
None
No oral-breathing,
but nasal congestion 
(＋) 
Severe nasal
congestion with
occasional
oral-breathing
Very severe nasal
congestion with
frequent oral-breathing
Complete
congestion,
al day
Nasal congestion
If scored, ＋＋＋＋: 4-points, ＋＋＋: 3-points, ＋＋: 2-points, ＋: 1-point, －: 0-point.
Daytime symptoms: after rising until bedtime.
Adapted from the Practical Guideline for the Management of Alergic Rhinitis in Japan, 2002 edition (the Fourth Revised Edition).5
Table 3 Severity of nightime nasal symptoms (NNSS)
Severity
Types
－＋＋＋＋＋＋＋＋＋＋
Not at alSlightly badBadVery badUnable to sleep at alDificulty infaling asleep
No nasal
congestion
Nasal congestion 
(＋), but not
bothering
Nasal congestion 
occasionaly
bothered
Persistent nasal 
congestion with 
oral-breathing
Severe nasal 
congestion with
persistent
oral-breathing
Nasal
congestion at
night
NoneOnce2 times3 times＝4 timesAwakening atnight
If scored, ＋＋＋＋: 4-points, ＋＋＋: 3-points, ＋＋: 2-points, ＋: 1-point, －: 0-point.
Nightime symptoms: after bedtime until rising the folowing morning.
nighttime nasal symptoms (difficulties in falling into
sleep, nasal congestion at night, and degree of awak-
ening at night)2 points per day, as an average (total
6 points)] (Table 2, 3). The study was performed
when the patients fulfilled these two inclusion crite-
ria. The patients with nasal disorders that might inter-
fere with the efficacy assessment, or those using
drugs that might interfere with the efficacy assess-
ment were excluded from the study. Patients who
used any drug that might affect efficacy assessment
in the study within 2 weeks prior to the observation
period such as anti-histamines, leukotriene receptor
antagonists, anti-thromboxane A2 drugs, chemical
mediator release inhibitors, Th2 cytokine inhibitors,
corticosteroids (topical and systemic), vasoconstric-
tors, parasympathetic nerve blockers ( anti-
cholinergic), biological preparations (histamine-
containing immunoglobulin), tranquilizers (anti-
depressants, anti-psychotics, and CNS suppressants),
and other drugs with similar pharmacological activi-
ties to the above-mentioned drugs (herbal medica-
tions that are expected to have anti-allergic patients
with uncontrolled mild to moderate symptoms). Pa-
tients with severe bronchial asthma were also ex-
cluded from the study.
DOSAGE AND ADMINISTRATION
Montelukast sodium 5-mg10-mg tablets and the cor-
responding placebo tablets were administered orally
once daily (one tablet per day) at bedtime for two
weeks. Pranlukast hydrate 112.5-mg capsule, a con-
trol drug, and the corresponding placebo capsule
were administered orally twice daily, after breakfast
(2 capsules) and after dinner (2 capsules).
STUDY DESIGN
The study was a multiple center, randomized, double
blind non-inferiority study, compared with pranlukast
and conducted during the spring season of 2005. The
study period consisted of a 4-day run-in period and a
two-week treatment period. The treatment period was
determined by the previous overseas results that
showed that montelukast reached its almost maximal
therapeutic effect, compared with placebo within 2
weeks.5 The patients were randomized to a 1 : 1 : 1 ra-
tio to receive either montelukast 5 mg, 10 mg, or
pranlukast 450 mg groups (total six patients in one
block) by the permuted-block method. The study pro-
tocol was approved by each institutional review
board, and all patients gave written informed consent
to participate. The patients who fulfilled the inclusion
criteria were enrolled after the informed consent to
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Table 4 Composite nasal symptom scores (CNSS)
Changes from baselineMean Scores
NTreatment group
P value†95% Confidence interval
LS 
meanSDMean
Post-
treatmentBaseline
Montelukast
5 mg group 0.000 (－0.25, －0.14) －0.190.58－0.201.802.00461
Montelukast
10 mg group 0.000 (－0.25, －0.13) －0.190.59－0.201.832.03454
Pranlukast
450 mg group 0.000 (－0.26, －0.14) －0.200.59－0.221.802.02456
†Mean for the 2-week treatment period compared with the baseline value (based on ANCOVA model which contains the treatment 
group, study site and day of randomization as factors and the baseline as a covariate).
Table 5 Comparison of composite nasal symptom scores (CNSS) between the treatment groups
95% confidence interval 
for diferences†
Diference in changes
(LS mean)Comparison between groups
 (－0.0587, 0.0788) 0.01Montelukast 10 mg group―Pranlukast 450 mg group
 (－0.0619, 0.0752) 0.01Montelukast 5 mg group― Pranlukast 450 mg group
 (－0.0651, 0.0719) 0.00Montelukast 10 mg group― Montelukast 5 mg group
†Δ＝0.085. Non-inferiority was tested via a stepped down procedure.
participate in this study was obtained. Nasal symp-
toms based on physical examinations and rhinitis-
diaries were checked at each patient visit. Clinical
and laboratory examinations were performed to as-
sess the safety at the time of initiation of the therapy
and at week-2 of treatment or at the time of discon-
tinuation.
EVALUATION OF EFFICACY AND SAFETY
As a primary endpoint, the daily means of the com-
posite nasal symptom scores (CNSS) (average of na-
sal symptom scores during the daytime and the
nighttime) over the 2 week treatment period, were
compared with those during the run-in period. As
secondary endpoints, the following symptoms were
investigated: (1) daytime nasal symptoms scores
(DNSS) (mean score of nasal congestion, nasal dis-
charge and sneezing), (2) nighttime nasal symptoms
scores (NNSS) (mean score of severity of nasal con-
gestion at night, difficulty in falling asleep and degree
of awakening at night), (3) composite nasal conges-
tion scores (mean of nasal congestion scores during
the day and at night). The patient’s and investigator’s
impressions (both assessed by a 6-point rating scale)
were assessed with regard to the efficacy. The use of
CNSS, DNSS and NNSS as the primary and secon-
dary endpoints have been recommended in the Guid-
ance for Industry, Allergic Rhinitis: Clinical Develop-
ment for Programs for Drug Products (FDA CDER,
www.fda.govcderguidance2718dft.htm, last up-
dated on March 08, 2001).
Clinical and laboratory adverse experiences were
investigated. The drug-related adverse experiences
were also evaluated.
STATISTICAL ANALYSIS
The full analysis set (FAS) was defined as the pri-
mary efficacy analysis population. Comparison of the
change from baseline over 2 weeks in the CNSS be-
tween treatment groups was performed using an
analysis of covariance (ANCOVA) model which con-
fains the treatment group, study site and day of ran-
domization as factors and the baseline as a covariate.
Non-inferiority of montelukast to pranlukast was
evaluated using the two-sided 95% upper confidence
limit of the between-group difference in LS (least
square) means of the change from the baseline in the
CNSS (non-inferiority margin, ∆ = 0.085). A step-
down procedure was used in demonstrating the non-
inferiority (i.e. if non-inferiority is demonstrated in
montelukast 10 mg then montelukast 5 mg is evalu-
ated). The patient’s and investigator’s impressions
were analyzed (the percentage of ‘much improved’
and ‘improved’) using a Pearson’s chi-square test
with step-down procedure. Significance level in this
study is two-sided 5%.
The incidences of adverse experiences (AE) and
drug related AE as well as their 95% confidence inter-
vals were calculated, and these were compared using
Fisher’s exact test.
RESULTS
A total of 1375 patients were randomized (462, 457
and 456 patients for the montelukast 5 mg, 10 mg and
Montelukast for Allergic Rhinitis (II)
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Fig. 1 Mean of composite nasal symptom Scores for the 2-
week treatment period. ＊p＜0.05 compared with baseline.
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pranlukast 450 mg groups, respectively), and 1371 pa-
tients completed the study, and were subjected to
FAS for efficacy analysis, while 4 patients (one and
three patients for montelukast 5 mg and 10 mg, re-
spectively) discontinued the study. All 1375 patients
were subjected to the safety analysis. The demo-
graphics and other baseline characteristics of the
1371 patients included in the efficacy analysis were
described in Table 1. There were no clinically signifi-
cant differences of the baseline patient characteristics
among the three groups.
EFFICACY ANALYSIS
As shown in Figure 1 and described in Table 4, 5, the
change from the baseline (LS mean ± SE) in the
CNSS over 2 weeks for each treatment group is
shown in Figure 1. The LS mean changes from the
baseline in the CNSS over 2 weeks were −0.19, −0.19
and −0.20 points for the montelukast 5 mg, 10 mg and
pranlukast 450 mg, respectively, demonstrating sig-
nificant improvements compared to the baseline (P <
0.001 for all three groups).
The difference in LS mean for the change between
the two groups (montelukast 10 mg − pranlukast 450
mg) was 0.01 point with a 95% confidence intervals
(CI) (−0.0587, 0.0788) point. Since the 95% upper con-
fidence limit of the difference was less than the non-
inferiority margin (∆ = 0.085), the non-inferiority of
montelukast 10 mg to pranlukast 450 mg was demon-
strated. In addition, there was no significant differ-
ence between montelukast 10 mg and pranlukast 450
mg.
Similarly the between-group difference (montelu-
kast 5 mg − pranlukast 450 mg) was 0.01 point with a
95% CI (−0.0619, 0.0752) point. Thus, the non-
inferiority of montelukast 5 mg to pranlukast 450 mg
was demonstrated. In addition, there was no signifi-
cant difference among the three groups.
The changes in the mean DNSS and DNSS con-
stituents for the 2-week treatment period from the
baseline (LS mean ± SE) are shown in Figure 2. The
changes in the mean DNSS for the 2-week treatment
period from the baseline (LS mean) were −0.17, −0.16
and −0.20 points for the montelukast 5 mg, 10 mg and
pranlukast 450 mg groups, respectively, demonstrat-
ing significant improvements compared to the base-
line (P < 0.001 for all three groups).
As for each component of the nasal symptom
scores, the changes in the mean daytime nasal con-
gestion scores for the 2-week treatment period from
the baseline (LS mean) were −0.29, −0.26 and −0.31
points for the montelukast 5 mg, 10 mg and pranlu-
kast 450 mg groups, respectively, demonstrating sig-
nificant improvements compared to the baseline (P <
0.001 for all three groups).
The changes in the mean nasal discharge scores
for the 2-week treatment period from the baseline (LS
mean) were −0.07, −0.07 and −0.10 points for the
montelukast 5 mg, 10 mg and pranlukast 450 mg
groups, respectively, demonstrating significant im-
provements compared to the baseline for the mon-
telukast 10 mg and pranlukast 450 mg groups (P =
0.046 and P = 0.010 for montelukast 10 mg and pran-
lukast 450 mg groups, respectively), although there
was no significant difference between the montelu-
kast 5 mg group and the baseline.
The changes in the mean sneezing attack scores
for the 2-week treatment period from the baseline (LS
mean) were −0.14, −0.16 and −0.19 points for the
montelukast 5 mg, 10 mg and pranlukast 450 mg
groups, respectively, demonstrating significant im-
provements compared to the baseline (P < 0.001 for
all three groups).
The changes in the mean NNSS and NNSS con-
stituents for the 2-week treatment period from the
baseline (LS mean ± SE) are shown in Figure 3. The
changes in the mean NNSS were −0.23, −0.22 and
−0.21 points for the montelukast 5 mg, 10 mg and
pranlukast 450 mg groups, respectively, demonstrat-
ing significant improvements compared to the base-
line (P < 0.001 for all three groups).
As for each component, the changes in the mean
nighttime nasal congestion scores for the 2-week
treatment period from the baseline (LS mean) were
−0.31, −0.27 and −0.29 points for the montelukast 5
mg, 10 mg and pranlukast 450 mg groups, respec-
tively, demonstrating significant improvements com-
pared to the baseline (P < 0.001 for all three groups).
The changes in the mean difficulty scores (to fall
into sleep) for the 2-week treatment period from the
baseline (LS mean) were −0.25, −0.27 and −0.23
points for the montelukast 5 mg, 10 mg and pranlu-
kast 450 mg groups, respectively, demonstrating sig-
nificant improvements compared to the baseline (P <
Okubo K et al.
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Fig. 2 Mean of daytime nasal symptom scores for the 2-week treatment period.
＊p＜0.05 compared with baseline.
－0.4
－0.2
0
＊ ＊
＊
＊
＊
＊
＊
＊
＊
＊
＊
Daytime nasal symptom
scores (DNSS)  
Daytime nasal
congestion 
Sneezing attack
scores 
Nasal discharge
scores 
C
ha
ng
es
 fr
om
 b
as
el
in
e 
(L
S
 m
ea
n 
±
 S
.E
.)
 
Montelukast 5 mg Montelukast 10 mg Pranlukast 450 mg
Fig. 3 Mean of nightime nasal symptom scores for the 2-week treatment period.
＊p＜0.05 compared with baseline.
－0.4
－0.2
0
Montelukast 5 mg Montelukast 10 mg Pranlukast 450 mg
Nighttime nasal symptom
scores (NNSS)  
Nighttime nasal
congestion 
Difficulty in
falling asleep at 
night 
Degree of
awakening at night  
C
ha
ng
es
 fr
om
 b
as
el
in
e 
(L
S
 m
ea
n 
±
 S
.E
.)
 
＊ ＊
＊
＊
＊
＊
＊
＊
＊
＊ ＊
＊
0.001 for all three groups).
The changes in the mean scores (to assess degree
of awakening at night) for the 2-week treatment pe-
riod from the baseline (LS mean) were −0.14, −0.14
and −0.12 points for the montelukast 5 mg, 10 mg and
pranlukast 450 mg groups, respectively, demonstrat-
ing significant improvements compared to the base-
line (P < 0.001 for all three groups).
In addition, there was no significant difference in
the mean scores of all the parameters during the day-
time and at night for the 2-week treatment period be-
tween the montelukast 5 mg and 10 mg groups. The
scores in the montelukast 5 mg and pranlukast 450
mg groups were not compared because there was no
significant difference between montelukast 10 mg
and pranlukast 450 mg groups.
Furthermore, there was no significant difference in
the rates of patient’s and investigator’s impression be-
Montelukast for Allergic Rhinitis (II)
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tween the montelukast 10 mg group and pranlukast
450 mg group (P = 0.379 and P = 0.907, respectively).
Thus, the rates of patient’s and investigator’s impres-
sion between the montelukast 5 mg group and pran-
lukast 450 mg group were not compared.
SAFETY ANALYSIS
There was no significant difference in the incidence
of AE among the montelukast 5 mg, 10 mg and pran-
lukast 450 mg groups. The incidences of AE were
24.9%, 24.3% and 23.5% for clinical AE and 2.8%, 2.9%
and 5.5% for laboratory AE in the montelukast 5 mg,
10 mg and pranlukast 450 mg groups, respectively.
The incidences of drug-related AE were 4.8%, 4.2%
and 3.7% for clinical AE and 2.4%, 2.0% and 3.5% for
laboratory AE in the montelukast 5 mg, 10 mg and
pranlukast 450 mg groups, respectively. There was
also no significant difference in the incidence of clini-
cal AE or drug-related clinical AE of the montelukast
5 mg and 10 mg groups compared with the pranlu-
kast 450 mg group. Although the incidence of labora-
tory AE was significantly lower in the montelukast 5
mg and 10 mg groups compared with the pranlukast
450 mg group (P < 0.05), there was no difference in
the incidence of the drug-related laboratory AE
among the groups.
“Nasopharyngitis” and “headache” were AE that
occurred in more than 3% in any of the three groups.
In addition, “diarrhea”, ”thirst” and “somnolence”
were drug-related AE that occurred in more than 1%
in any of the three groups. Each one patient in the
montelukast 5 mg and 10 mg groups discontinued
the study due to “diarrhea”, and they were rated as
serious drug-related AE. These two patients recov-
ered shortly after discontinuation of the study and the
physicians-in-charge judged that there was no clinical
problem. All other symptoms were mild in intensity,
and there was no clinically problematic finding.
There was no difference in the safety profile between
the montelukast 5 mg and 10 mg groups.
DISCUSSION
In the present study, we have conducted a double
blind non-inferiority study of montelukast, compared
with pranlukast to evaluate the efficacy and safety of
montelukast in patients with seasonal allergic rhinitis.
We selected pranlukast as a control drug because
pranlukast exerts its pharmacological actions
through the same mechanisms as montelukast and it
is the only drug that has been approved for allergic
rhinitis and it has been widely used in the clinical set-
ting in Japan.2 In terms of the primary endpoints, the
CNSS, non-inferiority of montelukast 10 mg and mon-
telukast 5 mg to pranlukast 450 mg was demon-
strated. With regard to the other endpoints, there
was no difference among the three treatment groups,
the nasal symptoms improved to a comparable extent
in all three groups. Taken together, these results
have demonstrated that the efficacy of montelukast
lasts for two weeks in patients with allergic rhinitis
and that montelukast is as effective as pranlukast.
Montelukast and pranlukast have been expected to
improve nasal congestion, based on their mecha-
nisms of actions, and in the present study, both drugs
indeed improved nasal congestion as well as the
other symptoms associated with allergic rhinitis, in-
cluding sneezing attacks and nasal discharge. With
regard to its efficacy against nasal congestion, it has
been stated in the Practical Guideline for the Man-
agement of Allergic Rhinitis in Japan (2005 Edition)
that leukotriene receptor antagonists are effective pri-
marily for treatment of moderate to severe “nasal
congestion-type” allergic rhinitis.3 We also confirmed
the efficacy of leukotriene antagonists for improving
nasal congestion. A multi-center, randomized, double
blind, comparative study of pranlukast was con-
ducted, using epinastine hydrochloride as a control
drug,8 and it has been reported that pranlukast was
efficacious in patients whose major complaint was na-
sal congestion. In addition, it has been reported that
pranlukast was also effective against sneezing and na-
sal discharge.8 A multi-center, randomized, double
blind study of montelukast was conducted overseas,
using loratadine as a control drug,9 and montelukast
was shown to be effective for improving nasal conges-
tion and also for improving the nasal symptoms at
night. In the present study, we obtained comparable
results.
In the present study, the changes in the CNSS
from the baseline (LS mean) were −0.19 for both
montelukast 10 mg and montelukast 5 mg, smaller
than that obtained in the previous study (−0.47).5
Since the amounts of pollen scattered during the
study period in this study were approximately 20
times higher than those reported in the pollen re-
ports10 in the previous study,7 the result was attribut-
able to differences in the amounts of pollen scattered
during the study period. In addition, montelukast 10
mg improved the nasal symptoms numerically better
than montelukast 5 mg (data not shown). The results
were similar to those reported in the previous study.5
Thus, when symptoms become severe due to a large
quantity of pollen scattered, these results suggest
that montelukast may be more effective at a daily
dose of 10 mg.
We investigated the safety of the study drugs,
mainly based on the incidence rates of adverse expe-
riences (AE) and drug-related AE (clinical and labora-
tory tests findings). There were no significant differ-
ences in the incidence of clinical AE and drug-related
AE among the three groups. Thus, montelukast was
well tolerated and as safe as pranlukast at daily doses
of 5 mg and 10 mg for two weeks, and there was no
difference in the safety profiles between montelukast
and pranlukast. In addition, there was no AE that oc-
curred anew in adult patients with allergic rhinitis in
Okubo K et al.
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Japan.
In conclusion, the results of the present study indi-
cate that montelukast is efficacious and safe for the
treatment of seasonal allergic rhinitis, alleviating
overall symptoms, including nasal congestion, sneez-
ing and nasal discharge, as seen in the clinical stud-
ies conducted overseas.11-15
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